Navigation Links
Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety
Date:12/10/2010

NEW YORK, Dec. 10, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced today that, in the interest of patient safety, it is voluntarily withdrawing Thelin® (sitaxentan) for the treatment of pulmonary arterial hypertension (PAH) in regions where it is approved (the European Union, Canada and Australia).  In addition, Pfizer is discontinuing clinical studies of Thelin worldwide.

(Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO)

Pfizer's decision was based on a review of emerging safety information from clinical trials and post-marketing reports.  While liver toxicity is a known complication of the class of drugs to which Thelin belongs, a new potentially life-threatening idiosyncratic risk of liver injury with Thelin has been observed. Given the availability of alternate treatments, Pfizer has concluded that the overall benefit of Thelin no longer outweighs the risk in the general population of PAH patients.  The Company has notified health authorities about this finding and its decision to voluntarily withdraw Thelin from the market and stop clinical studies.  

"Pfizer's priority is to ensure the safety and well-being of patients, and we are in the process of communicating all of this information to the appropriate medical professionals and regulatory authorities in all regions as quickly as possible," said Cara Cassino, MD, vice president, Clinical Development and Medical Affairs for Pfizer's Pulmonary Vascular Disease unit.

Pfizer recommends that no new patients be prescribed Thelin and that patients receiving Thelin be transitioned to appropriate alternate therapies as soon as safely possible according to best local practice.  Patients taking Thelin or participating in Thelin studies are advised to consult with their health care professional as soon as possible.  Patients should not stop takin
'/>"/>

SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Biovista Announces a Drug Repositioning Collaboration With Pfizer
2. MacroGenics Enters Global Research Collaboration and License Agreement with Pfizer
3. Pfizer, Merck, Roche/Genentech, GSK, J&J, BMS and More to Speak at Contracting & Outsourcing 2010
4. Pfizer Wins CIO 100 Award for Patient Enrollment Optimization Solution From DecisionView
5. Pfizer Announces EMPHASIS-HF Trial to Halt Recruitment due to Significant Benefit Observed in Patients Treated With Inspra® (Eplerenone)
6. Pfizer Animal Health Expands Global Commitment to a Safe Food Supply with a New Focus on Healthy Fish
7. Oramed Pharmaceuticals Announces That Dr. Michael Berelowitz, Senior Vice President at Pfizer, Joins its Board of Directors
8. Pfizer Global Manufacturing Announces Plans to Reconfigure Its Global Plant Network
9. Anavex comments on failure of Pfizer and Medivations Alzheimers investigational drug Dimebon during Phase 3 clinical trials
10. Wyeth Announces Stockholder Approval of Pfizer Merger at 2009 Annual Meeting
11. Pfizer Global R&D Presents 2008 Top Intermediates CMO Award to Asymchem
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Controlled Substance Compliance ... which helps companies check the legal requirements around using ... to China. , As their international operations expand ... adopting software solutions built as a result of the ...
(Date:1/22/2015)... , 22 de enero de 2015  El Dr. ... su llamada a nominaciones para 2015. Este prestigioso premio ... o tiene el potencial para hacer, contribuciones destacadas para ... aceptarán hasta el 15 de marzo de 2015 a ...
(Date:1/22/2015)... 2015   GenoSpace , a precision medicine software company that ... broad use of genomic, imaging and other biomedical data in ... Michelle Munson , CEO of Aspera, an IBM Company, to ... http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased to ...
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... (NYSE: MDT ) has submitted a pre-market ... (FDA) for the use of Medtronic,s SynchroMed ® ... catheter) for use with United Therapeutics, Remodulin ® ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4GenoSpace Expands Board with Appointment of Michelle Munson 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... , , SAN FRANCISCO , Feb. ... ) acted as a placement agent in GenVec, Inc.,s (Nasdaq: ... shares of common stock, and warrants to purchase 4.2 million shares ... , (Logo:   http://www.newscom.com/cgi-bin/prnh/20090911/MCFLOGO ) , "We have been working with ...
... ... for Manufacture and Testing of Drug Products Imported to the European Union. ... Toronto, Ontario (PRWEB) ... to leading pharmaceutical companies, today announced successful completion of its recent Health Canada audit. ...
... , FORT LAUDERDALE, Fla. , ... published in EuroIntervention (EuroIntervention, 2010; 5:698-702) demonstrated ... and no late stent thrombosis at one year in ... percutaneous coronary intervention (PCI) and implantation of the company,s ...
Cached Biology Technology:Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 2Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 3Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 4Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 5Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 6Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 7Dalton Pharma Services Announces Successful Completion of Health Canada Inspection 2Dalton Pharma Services Announces Successful Completion of Health Canada Inspection 3OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Demonstrates Good Safety and Clinical Outcomes in Patients with Primary PCI for STEMI 2OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Demonstrates Good Safety and Clinical Outcomes in Patients with Primary PCI for STEMI 3
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... of the "The Global Watermarking and Fingerprinting ... http://photos.prnewswire.com/prnh/20130307/600769 This ... media watermarking and fingerprinting markets. Watermarking aims to ...
(Date:12/19/2014)... and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) has announced ... - Apple/AuthenTec TMDR92 & Sapphire - Technology Report" ... http://photos.prnewswire.com/prnh/20130307/600769 Following the acquisition of AuthenTec ... with the iPhone 5S. It is currently the only ...
(Date:12/19/2014)... VIEW, Calif. , Dec. 18, 2014  23andMe, Inc., the ... study that pinpoints fine-scale differences in genetic ancestry of individuals ... Since immigrants first arrived more than four hundred years ... as a meeting place for peoples from different continents. This ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... Infection with West Nile virus (WNV) causes no symptoms ... encephalitis. What determines the outcome of infection with WNV in ... and colleagues, at the Blood Systems Research Institute, San Francisco, ... (immune cells that suppress the function of other immune cells) ...
... New Orleans, LA Dr. John England, Professor and ... analyzed research findings and was responsible for the quality and ... resulting in new guidelines for treating Lou Gehrig,s disease, or ... the October 13, 2009 issue of Neurology , the ...
... target to stem biodiversity loss by next year, according to ... to biodiversity science. The goal was agreed at ... Biological Diversity in April 2003. Some 123 world ministers ... current rate of biodiversity loss at the local, national and ...
Cached Biology News:LSUHSC's England plays key role in developing new ALS treatment guidelines 2World will miss 2010 target to stem biodiversity loss, experts say 2World will miss 2010 target to stem biodiversity loss, experts say 3World will miss 2010 target to stem biodiversity loss, experts say 4World will miss 2010 target to stem biodiversity loss, experts say 5World will miss 2010 target to stem biodiversity loss, experts say 6
... produced by a patented microwave process which ... consistent, even cell attachment, increased cell growth ... growth uunder difficult conditions, including reduced serum ... a more ecominic alternative to expensive and ...
Automated Cell Culture Flask...
... Bio-Plex suspension array system, 100-240 V, uses ... up to 100 proteins and peptides in ... composed of up to 100 color-coded bead ... with a unique reactant (enzyme substrates, receptors, ...
Cell Culture Flask, 75 cm, treated polystyrene...
Biology Products: